Slap restricts oncogenic Src-family kinase signaling to maintain colonic epithelial homeostasis

Reviewer #1 (Public review):

Naim et al. use genetically engineered mouse models and tissue culture cell lines to investigate the role of the SLAP adaptor protein in colonic epithelium and colon tumour formation. The SLAP adaptor protein is known to be a negative regulator of tyrosine kinase signaling in hematopoietic cells, but its role outside the immune system is less well defined. Here, the authors use genetically engineered SLAP-deficient mice, tissue-specific SLAP KO, and colonic organoids to demonstrate that SLAP is expressed in cells of the colonic epithelium, where it acts as a cell-autonomous regulator of proliferation and differentiation. In addition, they provide biochemical evidence that loss of SLAP expression in cultured colonic organoids results in increased Src family kinase activity and global tyrosine phosphorylation, consistent with its known role as a suppressor of tyrosine kinase activity in immune cells. Consistently, treatment with an SRC kinase inhibitor inhibited the growth of SLAP-deficient organoids. These data provide solid evidence of a cell-autonomous role of SLAP in the colonic epithelium.

This work would be improved by further description and interpretation of the SLAP expression pattern shown in the constitutive and tissue-specific KO to further support the conclusions made. In Supplementary Figure 1, magnification of the colon epithelium areas with SLAP expression shown by b-gal and anti-SLAP staining, highlighting regions of interest, would better support the conclusions regarding SLAP expression in specific regions of the colon epithelium. In Supplementary Figure 1B, the authors should indicate that the SLAP staining referred to is epithelial and in resident immune cells, as is mentioned in the text. Also, magnification of the boxed area of LRG5 staining in Figure 1 would improve this figure.

Using a chemically induced model of colitis-associated cancer, the authors demonstrate that inactivation of SLAP shows a trend toward increased tumor formation (though this did not reach significance) as well as increased Src family kinase activity within tumors. Tumor spheres from SLAP-deficient animals showed enhanced growth that was suppressed by treatment with a Src family kinase inhibitor. Of note, the latter effect was specific to SLAP-deficient tumor spheres. These observations are convincing and support the authors' conclusion that SLAP has a tumor suppressor role in CRC through inhibition of SFK signaling.

Mechanistically, elevated expression of the RTK, EphB2, was detected in immunoblots of SLAP KO colonic crypts, while overexpression of SLAP in CRC cell lines downregulated EphB2 protein levels. Using an EPHB2 inhibitor, the role of EPHB2 in the growth of SLAP-deficient colonic organoids was demonstrated. While these data generally support the authors' conclusion that SLAP limits colonic organoid growth by downregulating RTKS such as EphB2 and downstream Src family kinase activity, they do not show which cell types/regions in the colonic epithelium have increased EPHB2 protein and how this relates to SLAP and phospho-SRC expression, as shown in Figure 1 and Figure S1 immunocytochemistry. The expression of EphB2 and its role in colonic tumorsphere growth were not investigated.

Overall, this work provides evidence of SLAP adaptor function in restricting tyrosine kinase signaling in the colonic epithelium, and suggests that loss of SLAP expression could promote tumorigenesis in this context.

Reviewer #2 (Public review):

Summary:

Protein tyrosine kinases are subject to diverse regulatory mechanisms controlling their activity in normal situations. The authors previously identified SLAP (Src-like adaptor protein), a negative regulator of receptor tyrosine kinase (RTK) signaling, as a key suppressor of the cytoplasmic tyrosine kinase SRC in the normal colon and demonstrated that SLAP is downregulated in a majority of colorectal cancers (CRCs).

In this study, the authors further explored SLAP functions in mouse models using constitutive and inducible epithelial-specific Slap deletion (villin-CreERT2 model). They found that loss of SLAP augments colonic epithelial cell proliferation and that induction of tumorigenesis by the AOM/DSS protocol mimicking CRC leads to more aggressive tumors in the absence of SLAP. This effect is apparently cell-autonomous as growth of normal and tumoral colonic organoids is SLAP-dependent in in vitro settings. Finally, the authors define that, in colon, SLAP represses EphB2, an RTK lying upstream of SRC, and show that inhibitors of EphB2 can partially limit tumorigenic development in vitro.

Strengths:

The manuscript is clearly and concisely written, making it easy to follow. The data obtained in the mouse models are very convincing.

Weaknesses:

Direct evidence that EphB2 is activated/phosphorylated in the absence of SLAP is lacking, as conclusions are only based on results obtained with inhibitors. Some other issues have to be addressed before acceptance, in particular, the relevance of the findings in CRC patients.

Author Response:

Public Reviews:

Reviewer #1 (Public review):

Naim et al. use genetically engineered mouse models and tissue culture cell lines to investigate the role of the SLAP adaptor protein in colonic epithelium and colon tumour formation. The SLAP adaptor protein is known to be a negative regulator of tyrosine kinase signaling in hematopoietic cells, but its role outside the immune system is less well defined. Here, the authors use genetically engineered SLAP-deficient mice, tissue-specific SLAP KO, and colonic organoids to demonstrate that SLAP is expressed in cells of the colonic epithelium, where it acts as a cell-autonomous regulator of proliferation and differentiation. In addition, they provide biochemical evidence that loss of SLAP expression in cultured colonic organoids results in increased Src family kinase activity and global tyrosine phosphorylation, consistent with its known role as a suppressor of tyrosine kinase activity in immune cells. Consistently, treatment with an SRC kinase inhibitor inhibited the growth of SLAP-deficient organoids. These data provide solid evidence of a cell-autonomous role of SLAP in the colonic epithelium.

This work would be improved by further description and interpretation of the SLAP expression pattern shown in the constitutive and tissue-specific KO to further support the conclusions made. In Supplementary Figure 1, magnification of the colon epithelium areas with SLAP expression shown by b-gal and anti-SLAP staining, highlighting regions of interest, would better support the conclusions regarding SLAP expression in specific regions of the colon epithelium. In Supplementary Figure 1B, the authors should indicate that the SLAP staining referred to is epithelial and in resident immune cells, as is mentioned in the text. Also, magnification of the boxed area of LRG5 staining in Figure 1 would improve this figure.

We thank the reviewer for their positive and constructive evaluation of our work.

We agree that a more detailed description and visualization of SLAP expression in the colonic epithelium would strengthen our conclusions. In response, we will revise Fig 1 and S1 to better highlight SLAP expression patterns. Specifically, we will include higher-magnification images of the colonic epithelial regions in Suppl Fig 1, with clearly indicated regions of interest. We will also clarify in the legend of Suppl Figure 1B that SLAP staining is observed in both epithelial and resident immune cells, as described in the text. Additionally, we will provide a magnified view of the boxed area showing LGR5 staining in Figure 1 to improve clarity.

Using a chemically induced model of colitis-associated cancer, the authors demonstrate that inactivation of SLAP shows a trend toward increased tumor formation (though this did not reach significance) as well as increased Src family kinase activity within tumors. Tumor spheres from SLAP-deficient animals showed enhanced growth that was suppressed by treatment with a Src family kinase inhibitor. Of note, the latter effect was specific to SLAP-deficient tumor spheres. These observations are convincing and support the authors' conclusion that SLAP has a tumor suppressor role in CRC through inhibition of SFK signaling.

Mechanistically, elevated expression of the RTK, EphB2, was detected in immunoblots of SLAP KO colonic crypts, while overexpression of SLAP in CRC cell lines downregulated EphB2 protein levels. Using an EPHB2 inhibitor, the role of EPHB2 in the growth of SLAP-deficient colonic organoids was demonstrated. While these data generally support the authors' conclusion that SLAP limits colonic organoid growth by downregulating RTKS such as EphB2 and downstream Src family kinase activity, they do not show which cell types/regions in the colonic epithelium have increased EPHB2 protein and how this relates to SLAP and phospho-SRC expression, as shown in Figure 1 and Figure S1 immunocytochemistry. The expression of EphB2 and its role in colonic tumorsphere growth were not investigated.

Overall, this work provides evidence of SLAP adaptor function in restricting tyrosine kinase signaling in the colonic epithelium, and suggests that loss of SLAP expression could promote tumorigenesis in this context.

We also thank the reviewer for their positive comments regarding our tumor studies and the role of SLAP in regulating SFK signaling.

Regarding the mechanistic insights involving EphB2, we appreciate the reviewer’s suggestion to further define its spatial expression and relationship with SLAP and phospho-SRC. To address this, we plan to extend our analysis to assess the effect of Slap depletion on EphB2 protein levels throughout the intestinal epithelium.

We recognize that directly testing EphB2’s role in murine colonic tumorsphere formation would require a new cohort of SLAP knockout mice treated with AOM/DSS for 90 days, which is not feasible in the short term. To address this, we will instead use human colorectal cancer models to assess how SLAP modulation affects the response of tumoroids derived from cell lines to EphB2 inhibition, providing complementary mechanistic insights.

Overall, we believe these additions will strengthen the manuscript and more fully address the reviewer’s concerns.

Reviewer #2 (Public review):

Summary:

Protein tyrosine kinases are subject to diverse regulatory mechanisms controlling their activity in normal situations. The authors previously identified SLAP (Src-like adaptor protein), a negative regulator of receptor tyrosine kinase (RTK) signaling, as a key suppressor of the cytoplasmic tyrosine kinase SRC in the normal colon and demonstrated that SLAP is downregulated in a majority of colorectal cancers (CRCs).

In this study, the authors further explored SLAP functions in mouse models using constitutive and inducible epithelial-specific Slap deletion (villin-CreERT2 model). They found that loss of SLAP augments colonic epithelial cell proliferation and that induction of tumorigenesis by the AOM/DSS protocol mimicking CRC leads to more aggressive tumors in the absence of SLAP. This effect is apparently cell-autonomous as growth of normal and tumoral colonic organoids is SLAP-dependent in in vitro settings. Finally, the authors define that, in colon, SLAP represses EphB2, an RTK lying upstream of SRC, and show that inhibitors of EphB2 can partially limit tumorigenic development in vitro.

Strengths:

The manuscript is clearly and concisely written, making it easy to follow. The data obtained in the mouse models are very convincing.

Weaknesses:

Direct evidence that EphB2 is activated/phosphorylated in the absence of SLAP is lacking, as conclusions are only based on results obtained with inhibitors. Some other issues have to be addressed before acceptance, in particular, the relevance of the findings in CRC patients.

We thank the reviewer for their positive and constructive evaluation of our work.

We agree that our conclusions regarding the SLAP–EphB2–SRC signaling axis rely in part on pharmacological inhibition. As outlined in the manuscript, EphB2 was selected primarily as a proof-of-concept receptor to illustrate how SLAP may indirectly regulate SRC activity through modulation of upstream receptor tyrosine kinases. We note that the use of two distinct classes of EphB inhibitors supports the robustness of our observations.

To further strengthen this aspect of the study, we will assess EphB2 phosphorylation status in SLAP-deficient conditions, which will provide more direct evidence of its activation state and its contribution to SRC signaling.